| |
Darryl L. Goss joins Bioreliance
Darryl L. Goss has been appointed Vice
President, Toxicology/Laboratory Animal Diagnostic Services (LADS), a new executive position created to lead this newly
formed Business Unit.
Click here to read the
press release.
|
|
|
|
|
The use of animal models to determine the toxicity of a pharmaceutical, biopharmaceutical or medical device is a required part of evaluating the overall safety of the product and predicting its effects on humans.
|
Back to Mammalian Toxicology
BioReliance has been a world leader in developing and providing preclinical safety studies for nucleic acid–based therapeutics, including gene therapies, viral oncolytics, DNA vaccines and other gene-based products. Studies offered include acute toxicity, repeat-dose safety tests and biodistribution studies. Biodistribution studies include the qualification and use of Q-PCR techniques to track the distribution and clearance of a vector and/or a gene. The use of reverse transcriptase PCR permits detection of gene expression by the vector.
Assays offered by BioReliance:
| Single or Repeated-Dose DNA Plasmid or Virus Vector Pharmacokinetics Studies |
9N91-6 |
|
 |
|
|
